On December 11, 2024, Noema Pharma AG announced that it has successfully closed a Series B extension financing round with an investment from EQT Life Sciences, bringing the total capital raised in the round to CHF 130 m (approx. USD 147 m). With its investment in Noema Pharma, EQT Life Sciences joins the syndicate of previous Series B investors including Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris Partners, Invus and UPMC Enterprises.

Noema Pharma is a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders characterized by imbalanced neuronal networks. The new financing will support Noema Pharma's four active Phase 2 trials, with key data readouts anticipated in 2025.

Homburger AG advised Noema Pharma AG as transaction counsel in this Series B extension financing round. The Homburger team comprised Andreas Müller, Thierry Burckhardt, Thomas Romelli and Rebecca Sigrist (all Corporate / M&A; Healthcare / Life Sciences), Luca Dal Molin (IP / IT; Healthcare / Life Sciences) as well as Stefan Oesterhelt and Laetitia Fracheboud (Tax).